Arcutis Biotherapeutics (ARQT) Stock Forecast & Price Target

Arcutis Biotherapeutics is expected to continue its growth trajectory in 2026 with the expansion of its salesforce and efforts to increase access to Zoryve, its lead product candidate. The company also has a promising pipeline with the potential for positive cash flows from its product ARQ234, currently in a phase 1 clinical trial. However, there are risks to consider, including dependence on a third party for supply and manufacturing, increasing operating expenses, and competition from generic and recently approved products. Overall, we maintain a positive outlook on the company, with potential for significant sales growth and positive cash flows in the future.

Arcutis Biotherapeutics is facing several potential risks, including dependence on FDA approvals for multiple indications for Zoryve, reliance on a third party for manufacturing, and the need for additional capital for commercialization and pipeline development. While the company had a solid 1Q26 with positive cash flows and increased market share for Zoryve, its 1Q seasonality, winter weather interruptions, and pullback in Rx growth may significantly impact its performance in future quarters. The company will need to carefully manage these risks and execute its commercialization plans to achieve its 2026 sales guidance of $455MM-$470MM.